At PHG, Dr. Erady has conducted evaluations of genomic projects, systematic reviews of novel biomarkers, market analysis for rare disease therapies, and assessed the potential of AI and novel computing methods in accelerating healthcare delivery.
She holds a PhD from the University of Cambridge for her computational analysis of multiomic data from neuropsychiatric samples and has supported market analysis and technology deployment in the UK and LMICs for charities and start-ups.
Key skills:
- AI, Quantum, Multiomics
- Rare diseases, Cancer, Neuroscience
- Data and Market analyses
- Policy and Insight analyses
- Workshop organisation and facilitation
- Babb de Villiers C, Plans-Beriso E, Erady C, Blackburn L, Wilson H, Turner H, Kuhn I, Barahona-López C, Diez-Echave P, Hernández OR, et al. Biomarkers for Personalised Primary or Secondary Prevention in Cardiovascular Diseases: A Rapid Scoping Review. International Journal of Molecular Sciences. 2025; 26(19):9346.
